IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Innovative Formulation Strategies for Solid Dispersions: Overcoming Challenges in Enhancing Solubility of BCS Class 2 Compounds

Mr. Somesh Rothe[1], Mr. Rahul Kalwe[2], Dr. Bhaskar Mohite[3], Dr. Aijaz Sheikh[4], Dr. Kailash Biyani[5]
Anuradha College of Pharmacy, Chickhli, Maharashtra, India

Abstract: *Controlled release tablets play a pivotal role in pharmaceutical formulations, offering targeted drug delivery and improved patient compliance. This review explores innovative approaches for modulating gastrointestinal absorption to achieve controlled and sustained release from tablets. The introduction provides a brief overview of controlled release tablets, emphasizing the significance of influencing drug absorption for achieving therapeutic efficacy. The objective is to highlight the need for innovative approaches in modulating gastrointestinal absorption, addressing current challenges in achieving controlled release. Physiological considerations in gastrointestinal absorption are examined, including the structure and function of the stomach and intestines, along with factors influencing drug absorption in different regions. Challenges in achieving controlled release, such as variability in gastric emptying times and pH-dependent solubility issues, are discussed. Conventional methods, such as enteric coatings and modified-release formulations, are explored alongside their limitations, emphasizing the incomplete control over drug release and the lack of adaptability to individual patient variations. The review then delves into novel strategies, including bioresponsive materials, carrier systems, and prodrug approaches, showcasing their potential in overcoming challenges associated with conventional methods. Technological advances, such as microfabrication techniques and 3D printing in gastrointestinal drug delivery, are examined, offering insights into customized tablets for controlled release. In vitro and in vivo assessment methods are detailed, covering simulated gastric and intestinal conditions, tools for predicting in vivo performance, and the use of animal models and clinical trials. The review concludes with an exploration of challenges and future perspectives, addressing biopharmaceutical variability and regulatory considerations. The findings provide a structured approach for formulators, researchers, and pharmaceutical scientists in advancing controlled release tablet development, paving the way for personalized and effective drug delivery.*

Keywords: controlled release tablets, gastrointestinal absorption, innovative approaches, drug delivery, sustained release, novel strategies, technological advances, personalized.

I. INTRODUCTION

A. Background

1. Overview of BCS Class 2 Drugs

The Biopharmaceutics Classification System (BCS) Class 2 encompasses a class of drugs characterized by high permeability and low aqueous solubility. This classification is pertinent to a diverse range of pharmaceutical compounds crucial for therapeutic interventions. Drugs falling within this class, such as carbamazepine and ketoconazole, pose formulation challenges due to their limited water solubility, despite being recognized for their high permeability, which underscores their significance in drug development.[1,2]

2. Significance of Solubility Enhancement in Drug Development

Solubility enhancement holds paramount importance in the realm of drug development, especially for BCS Class 2 drugs. The inherent low solubility of these compounds presents a bottleneck in achieving optimal bioavailability. The ability of a drug to dissolve and be absorbed in the gastrointestinal tract directly influences its therapeutic efficacy. Consequently, the quest for strategies to enhance solubility becomes imperative, aiming to overcome the challenges

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

associated with erratic dissolution patterns and inconsistent absorption profiles. Addressing solubility issues not only ensures a more predictable pharmacokinetic profile but also contributes to minimizing interpatient variability, thereby enhancing overall drug performance. [3,4]

In the subsequent sections of this review, we will delve into innovative approaches, particularly the utilization of solid dispersions, as a promising avenue for solubility enhancement. This exploration is grounded in the necessity to advance drug delivery technologies, ensuring the efficient translation of BCS Class 2 drugs from development to therapeutic application. [4,5]

B. Challenges in Solubility of BCS Class 2 Drugs

1. Brief Discussion on the Physicochemical Properties

The solubility challenges encountered in BCS Class 2 drugs are intricately linked to their specific physicochemical properties. These drugs often possess a complex interplay of characteristics such as high lipophilicity, large molecular size, and the presence of functional groups that hinder water solubility. The dominance of hydrophobic interactions over hydrophilic interactions results in reduced affinity for water molecules, leading to low solubility in aqueous environments. Additionally, the crystalline nature of many BCS Class 2 drugs further compounds the issue, creating barriers to dissolution and subsequent absorption.

Understanding these physicochemical attributes is pivotal for designing effective solubility enhancement strategies. The molecular structure, crystallinity, and lipophilic-hydrophilic balance must be considered in the development of formulations aimed at overcoming these inherent solubility challenges. [6,7]

2. Impact on Bioavailability and Therapeutic Efficacy

The limited solubility of BCS Class 2 drugs directly translates to challenges in their bioavailability, influencing the overall therapeutic efficacy. Insufficient dissolution of these drugs in the gastrointestinal tract results in incomplete absorption, leading to erratic plasma concentration profiles. This variability in drug absorption not only hampers the predictability of therapeutic outcomes but also necessitates higher doses to achieve the desired effect. [8]

The impact on therapeutic efficacy is particularly pronounced in time-sensitive treatments, where achieving and maintaining therapeutic concentrations swiftly is critical. Inadequate solubility can lead to suboptimal drug levels, potentially compromising the efficacy of the treatment. Hence, addressing solubility challenges becomes imperative not only for optimizing bioavailability but also for ensuring consistent and reliable therapeutic responses in the patient population.

In the subsequent sections, we will explore innovative approaches, with a particular focus on solid dispersions, as strategies to effectively mitigate these solubility challenges associated with BCS Class 2 drugs. [8]

II. SOLID DISPERSIONS: CONCEPT AND COMPOSITION

A. Definition and Types

1. Amorphous Solid Dispersions

Amorphous solid dispersions (ASDs) represent a pivotal strategy for enhancing the solubility of BCS Class 2 drugs. In ASDs, the drug is dispersed within a polymer matrix without forming a crystalline structure. This amorphous state disrupts the inherent crystalline lattice of the drug, resulting in increased molecular mobility and, consequently, improved solubility. The absence of a defined crystal structure enables enhanced dissolution rates, as the drug molecules can more readily interact with the surrounding aqueous environment.

The formulation of ASDs involves careful selection of polymers, plasticizers, and processing techniques to achieve an amorphous state. Common polymers used in ASDs include hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and copolymers like Soluplus. The amorphization process is typically achieved through methods such as spray drying, co-milling, or hot-melt extrusion. [9,10]

2. Crystalline Solid Dispersions

Crystalline solid dispersions, in contrast to their amorphous counterparts, involve the dispersion of the drug within a crystalline polymer matrix. While less common, this approach offers unique advantages, particularly in terms of

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

stability. The drug remains in a crystalline form but is dispersed at the molecular level within the polymer, preventing the formation of large drug crystals that could compromise solubility.

Crystalline solid dispersions require a careful balance between the drug and polymer properties to achieve optimal dispersion and stability. Polymers such as polyethylene glycol (PEG) and polyvinyl alcohol (PVA) are commonly used in this context. Techniques such as solvent evaporation and co-precipitation are employed to generate crystalline solid dispersions.

In the subsequent sections, we will delve into the formulation strategies, manufacturing techniques, and characterization methods employed in the development of both amorphous and crystalline [11]

B. Components of Solid Dispersions

1. Drug Substances

The choice of drug substance is a critical factor in the formulation of solid dispersions. BCS Class 2 drugs, characterized by their low aqueous solubility, necessitate careful consideration of the drug's physicochemical properties. The drug should possess compatibility with the selected polymeric carrier, facilitating effective dispersion and solubility enhancement. Furthermore, the concentration of the drug within the solid dispersion must be optimized to achieve the desired therapeutic effect.

In the case of amorphous solid dispersions, the drug substance is crucial in determining the amorphous nature of the formulation. For crystalline solid dispersions, the drug's crystallinity is preserved, requiring a delicate balance to ensure optimal dispersion within the polymer matrix.[12]

2. Polymeric Carriers

Polymeric carriers serve as the backbone of solid dispersions, providing a matrix in which the drug is dispersed. The choice of polymer profoundly influences the stability, dissolution characteristics, and overall performance of the solid dispersion. Various polymers, both synthetic and natural, are employed based on their biocompatibility, solubility-enhancing properties, and processability.

Common polymeric carriers include hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), and copolymers like Soluplus. These polymers not only aid in enhancing drug solubility but also contribute to the stability and uniformity of the dispersion.[13,14]

3. Stabilizers and Surfactants

Stabilizers and surfactants play a crucial role in preventing the recrystallization or agglomeration of the drug within the solid dispersion, ensuring its long-term stability and dissolution performance. Stabilizers, such as antioxidants or anti-recrystallization agents, are employed to mitigate the potential degradation of the drug during storage. Surfactants, on the other hand, aid in maintaining the dispersion of the drug within the polymer matrix, preventing its re-crystallization and improving wetting properties during dissolution.[15]

Careful selection and optimization of stabilizers and surfactants are essential to achieve a robust and stable solid dispersion formulation.

In the following sections, we will delve into specific formulation strategies, manufacturing techniques, and the characterization of solid dispersions, providing a comprehensive understanding of their role in enhancing the solubility of BCS Class 2 drugs.[15]

III. FORMULATION STRATEGIES FOR SOLID DISPERSIONS

A. Polymer Selection and Role

1. Biodegradable Polymers

Biodegradable polymers play a pivotal role in the formulation of solid dispersions, offering advantages in terms of sustainability, controlled drug release, and compatibility with biological systems. The use of biodegradable polymers aligns with the growing emphasis on environmentally friendly pharmaceutical formulations. These polymers undergo degradation in physiological conditions, resulting in non-toxic byproducts that are easily eliminated from the body.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Commonly employed biodegradable polymers include poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and polyhydroxyalkanoates (PHA). The biodegradability of these polymers not only contributes to reduced environmental impact but also supports controlled drug release, allowing for sustained therapeutic effects.[16]

2. Hydrophilic vs. Hydrophobic Polymers

The choice between hydrophilic and hydrophobic polymers in solid dispersion formulation is dictated by the desired drug release profile and the physicochemical properties of the drug substance.

Hydrophilic Polymers: Hydrophilic polymers, such as hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP), enhance drug solubility by promoting water uptake and facilitating rapid dissolution. These polymers are particularly useful for drugs with poor aqueous solubility, as they improve wetting properties and overall bioavailability.

Hydrophobic Polymers: Hydrophobic polymers, like polyvinyl acetate (PVA) and polyethylene glycol (PEG), are employed to encapsulate hydrophobic drugs within the solid dispersion matrix. This enhances drug stability, controls release kinetics, and provides a protective environment for the drug substance. Hydrophobic polymers are beneficial when sustained drug release is desired.

The selection of polymers is a delicate balance, considering the specific needs of the drug and the desired therapeutic outcomes. The compatibility between the drug and polymer, as well as the polymer's influence on the physical state of the drug (amorphous or crystalline), is crucial for the success of the solid dispersion formulation.[17]

In the subsequent sections, we will explore manufacturing techniques and methods employed to create effective solid dispersions, considering the unique requirements of BCS Class 2 drugs and the chosen polymers.

B. Manufacturing Techniques

1. Melting Methods (Fusion, Co-melting)

Fusion Method: The fusion method involves the physical blending of the drug and polymer at an elevated temperature until a homogeneous melt is achieved. The molten mixture is subsequently cooled and solidified, forming a solid dispersion. This method is effective for drugs and polymers with compatible melting points. Careful control of the temperature and duration of the melting process is essential to prevent degradation of the drug or polymer.

Co-melting: Co-melting extends the fusion method by introducing a co-melting agent, typically a third component that aids in the dispersion process. This can be another polymer or a co-former, strategically chosen to enhance drug-polymer compatibility and improve the overall stability of the solid dispersion. Co-melting facilitates a more controlled and uniform dispersion of the drug within the polymer matrix.[18]

2. Solvent Evaporation Methods (Spray Drying, Solvent Casting)

Spray Drying: Spray drying involves dissolving both the drug and polymer in a common solvent, followed by atomization of the solution into droplets. These droplets are then dried using hot air or inert gases, resulting in fine particles that constitute the solid dispersion. Spray drying is advantageous for its scalability, efficiency, and ability to produce amorphous solid dispersions. The choice of solvent and process parameters significantly influences the characteristics of the final formulation.

Solvent Casting: Solvent casting is a technique where a solution of the drug and polymer is cast into a mold, forming a thin film upon solvent evaporation. This method is particularly useful for creating films or coatings with controlled drug release properties. The slow evaporation of the solvent allows for the formation of a uniform solid dispersion, but careful consideration must be given to avoid phase separation or uneven distribution.[19]

3. High-energy Methods (Milling, Co-grinding)

Milling: Milling involves the mechanical reduction of drug particles to achieve a fine powder, followed by blending with the polymer. This method is effective in creating solid dispersions with reduced particle size, increased surface area, and enhanced drug-polymer interactions. Milling is particularly suitable for drugs with poor solubility and can be combined with various polymers to achieve the desired dispersion.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Co-grinding: Co-grinding involves the simultaneous grinding of the drug and polymer, facilitating intimate mixing and formation of the solid dispersion. This high-energy method enhances the homogeneity of the formulation and promotes better drug-polymer interactions. Co-grinding can be performed using various equipment, such as ball mills or vibrational mills, and offers versatility in the selection of grinding conditions.

Each manufacturing technique has its advantages and limitations, and the choice depends on the specific characteristics of the drug and polymer, as well as the desired attributes of the final solid dispersion. In the subsequent sections, we will explore the impact of these manufacturing techniques on the properties of solid dispersions and their implications for solubility enhancement in BCS Class 2 drugs.[20]

C. Combination Approaches

1. Solid Dispersions with Lipid-Based Formulations

Combining solid dispersions with lipid-based formulations offers a synergistic approach to enhance solubility and bioavailability, especially for BCS Class 2 drugs with high lipophilicity.

Solid Dispersions and Lipid Nanoparticles: Integrating solid dispersions with lipid nanoparticles creates a dual delivery system. The drug is dispersed both in the amorphous state within the polymer matrix and encapsulated in lipid nanoparticles. This hybrid approach leverages the benefits of increased surface area from solid dispersions and the enhanced solubilization capacity of lipids. Lipid-based carriers, such as nanostructured lipid carriers (NLCs) or liposomes, provide an additional dimension to controlled drug release, stability, and permeability.

2. Hybrid Systems for Optimal Solubility Enhancement

Hybrid systems encompass the combination of different drug delivery technologies, such as solid dispersions with other carrier systems, to achieve optimal solubility enhancement.

Solid Dispersions and Nanoparticles: Integrating solid dispersions with nanoparticles, including polymeric or inorganic nanoparticles, enhances the overall drug delivery profile. Nanoparticles provide additional avenues for sustained release, targeted delivery, and protection of the drug substance. This hybrid system synergistically improves the solubility and dissolution properties achieved by solid dispersions alone.

Solid Dispersions and Micelles: Combining solid dispersions with micellar systems, formed by amphiphilic surfactants, creates a hybrid approach that improves the drug's solubility and stability. Micelles solubilize the drug in their hydrophobic core, while the solid dispersion component contributes to increased dissolution rates. This combination is particularly effective for drugs requiring both enhanced solubility and prolonged release.

These combination approaches present innovative solutions to address the complex challenges associated with solubility enhancement. They offer a comprehensive strategy to maximize the benefits of different drug delivery technologies, providing improved bioavailability and therapeutic efficacy. In the subsequent sections, we will explore the implications and applications of these combination approaches in the context of BCS Class 2 drugs.[21,22]

IV. CHARACTERIZATION TECHNIQUES

A. Physicochemical Characterization

1. X-ray Diffraction (XRD) Analysis

Principle: X-ray diffraction (XRD) is a powerful technique used to analyze the crystallographic structure of solid materials, providing information about the arrangement of atoms within a crystal lattice.

Application in Solid Dispersions: XRD is employed to assess the crystalline or amorphous nature of the drug within the solid dispersion. Crystalline structures exhibit characteristic diffraction patterns, enabling the identification of crystal phases. In contrast, amorphous structures lack defined diffraction peaks. XRD analysis aids in confirming the success of amorphization strategies in solid dispersions, a crucial factor for enhancing drug solubility.[23]

2. Differential Scanning Calorimetry (DSC)

Principle: Differential Scanning Calorimetry (DSC) measures the heat flow associated with thermal transitions in a material, offering insights into its thermal behavior.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Application in Solid Dispersions: DSC is employed to detect changes in heat capacity related to transitions such as melting or crystallization. In the context of solid dispersions, DSC is crucial for identifying the thermal behavior of both the drug and the polymer. The absence of characteristic drug melting peaks in DSC thermograms indicates successful amorphization within the solid dispersion. Additionally, DSC assists in understanding the compatibility between the drug and polymer, providing valuable information for formulation optimization.

In the subsequent sections, we will delve into additional physicochemical characterization techniques, including morphological analysis and spectroscopic methods, contributing to a comprehensive understanding of the properties and behavior of solid dispersions.[24]

B. Morphological Analysis

1. Scanning Electron Microscopy (SEM)

Principle: Scanning Electron Microscopy (SEM) is a high-resolution imaging technique that uses a focused beam of electrons to scan the surface of a sample. The resulting images provide detailed information about the sample's topography, surface structure, and morphology.

Application in Solid Dispersions: SEM is employed to examine the surface morphology and particle size of solid dispersion formulations. It offers insights into the homogeneity of the dispersion, the distribution of drug particles within the polymer matrix, and the overall physical structure. SEM images help assess the effectiveness of different manufacturing techniques and formulation strategies, allowing for the optimization of solid dispersion preparation.[25]

2. Transmission Electron Microscopy (TEM)

Principle: Transmission Electron Microscopy (TEM) involves passing electrons through a thin specimen, creating high-resolution images of internal structures. This technique provides detailed information about the internal morphology of particles.

Application in Solid Dispersions: TEM is particularly useful for visualizing the internal structure of solid dispersions at the nanoscale. It offers insights into the distribution of drug particles within the polymer matrix, revealing details about particle size, shape, and homogeneity. TEM is instrumental in confirming the amorphous state of the drug and assessing the overall structural integrity of the solid dispersion.

These morphological analyses, in conjunction with other characterization techniques, contribute to a comprehensive understanding of the physical properties of solid dispersions. In the subsequent sections, we will explore additional spectroscopic methods employed for characterization, shedding light on the chemical interactions and molecular dynamics within solid dispersion formulations.[26]

C. Spectroscopic Techniques

1. Fourier-Transform Infrared Spectroscopy (FTIR)

Principle: Fourier-Transform Infrared Spectroscopy (FTIR) measures the absorption of infrared light by a sample, providing information about its chemical composition and molecular structure.

Application in Solid Dispersions: FTIR is employed to analyze the interactions between the drug and polymer within solid dispersions. It identifies characteristic functional groups and chemical bonds present in the formulation. Changes in peak positions or intensities indicate potential interactions or modifications in the molecular structure, aiding in the assessment of drug-polymer compatibility. FTIR is particularly valuable for confirming the absence of chemical reactions and ensuring the stability of the solid dispersion components.

2. Nuclear Magnetic Resonance (NMR)

Principle: Nuclear Magnetic Resonance (NMR) spectroscopy analyzes the magnetic properties of atomic nuclei in a magnetic field. It provides information about the molecular structure, chemical environment, and interactions within a sample.

Application in Solid Dispersions: NMR is employed to study the molecular dynamics of solid dispersions, offering insights into the distribution of the drug within the polymer matrix. Through techniques such as solid-state NMR, the amorphous or crystalline state of the drug can be confirmed. NMR also aids in understanding the physical state of the

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

polymer and detecting any potential changes in its conformation due to interactions with the drug. Overall, NMR contributes valuable information about the structural aspects and interactions within the solid dispersion.

In the subsequent sections, we will explore additional in vitro and in vivo assessment methods, providing a comprehensive overview of the tools and techniques used to evaluate the performance of solid dispersions in the context of enhanced drug solubility for BCS Class 2 drugs.[27]

V. IN VITRO AND IN VIVO EVALUATION

A. In Vitro Dissolution Studies

1. Apparatus and Conditions

Apparatus: In vitro dissolution studies are typically conducted using various dissolution apparatus, with the choice dependent on the specific requirements of the drug and formulation. Commonly used apparatus include the USP paddle apparatus or the USP basket apparatus, simulating physiological conditions in the gastrointestinal tract.

Conditions: Dissolution studies are performed under controlled conditions, including temperature, pH, and agitation. Mimicking the physiological environment, the temperature is often maintained at 37°C, and the dissolution medium adjusted to relevant pH levels corresponding to different regions of the gastrointestinal tract. Agitation ensures uniform drug release and dispersion.

2. Dissolution Enhancement Profiles

Sampling and Analysis: Samples are withdrawn at specific time intervals, and the amount of drug dissolved is quantified. Analytical techniques such as high-performance liquid chromatography (HPLC) or UV-visible spectroscopy are employed to measure drug concentrations in the dissolution medium.

Dissolution Enhancement Profiles: Dissolution profiles provide crucial information about the release kinetics and solubility of the drug from the solid dispersion. The comparison of dissolution profiles between the solid dispersion and the pure drug offers insights into the effectiveness of the formulation in enhancing drug solubility. Parameters such as dissolution efficiency, mean dissolution time, and percentage of drug released at various time points contribute to a comprehensive understanding of the dissolution behavior.

In vitro dissolution studies serve as a fundamental step in assessing the performance of solid dispersions, providing valuable information on the formulation's ability to enhance drug solubility under simulated physiological conditions. In the subsequent sections, we will explore in vivo studies, animal models, and clinical evaluations to further evaluate the effectiveness of solid dispersions for BCS Class 2 drugs.[28]

B. Preclinical and Clinical Studies

1. Pharmacokinetic Studies

Preclinical Studies: In preclinical pharmacokinetic studies, animal models are employed to assess the absorption, distribution, metabolism, and excretion (ADME) of the drug from the solid dispersion formulation. Blood samples are collected at predetermined intervals, and pharmacokinetic parameters such as Cmax (peak plasma concentration), Tmax (time to reach peak concentration), and AUC (area under the curve) are determined. These studies provide insights into the systemic exposure and overall pharmacokinetic profile of the drug.

Clinical Studies: Clinical pharmacokinetic studies extend these evaluations to human subjects. Human trials involve administering the solid dispersion formulation to healthy volunteers or patients, followed by the collection of blood samples for analysis. The pharmacokinetic parameters obtained from clinical studies contribute to understanding the formulation's performance in the human body, guiding dosing regimens, and ensuring safety and efficacy.

2. Bioavailability Assessments

Preclinical and Clinical Bioavailability Studies: Bioavailability assessments focus on the fraction of the drug that reaches the systemic circulation and the rate at which this occurs. In preclinical studies, bioavailability is assessed in animal models, while clinical bioavailability studies involve human subjects. Comparisons between the bioavailability of the solid dispersion formulation and the reference formulation (e.g., pure drug or other formulations) provide critical information about the formulation's impact on drug absorption.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Bioequivalence Studies: In clinical settings, bioequivalence studies may be conducted to demonstrate the comparable performance of the solid dispersion formulation to a reference formulation. This involves comparing the bioavailability of the drug from both formulations, ensuring that they are equivalent in terms of rate and extent of absorption. Regulatory agencies often require bioequivalence studies to support the approval of generic formulations.

Preclinical and clinical studies are essential steps in evaluating the translational potential of solid dispersions. These studies bridge the gap between in vitro dissolution assessments and real-world performance, providing crucial data for regulatory submissions and guiding the formulation's clinical application.[29]

VI. CHALLENGES AND LIMITATIONS

A. Stability Issues

1. Physical Stability

Agglomeration and Recrystallization: Solid dispersions are susceptible to physical instability, manifesting as agglomeration or recrystallization of the drug within the formulation. Agglomeration can lead to uneven drug distribution, affecting dissolution properties, while recrystallization may compromise the amorphous state achieved during formulation. These phenomena are influenced by factors such as storage conditions, temperature, and the choice of excipients.

Hygroscopicity: The hygroscopic nature of certain drugs and polymers poses a challenge, leading to moisture uptake and potential changes in the physical properties of the solid dispersion. Hygroscopicity can impact drug stability, alter dissolution profiles, and affect long-term storage viability.

2. Chemical Stability

Chemical Interactions: Chemical interactions between the drug and polymer or other excipients may occur, impacting the chemical stability of the formulation. These interactions can lead to degradation of the drug or excipients, potentially resulting in reduced therapeutic efficacy or the formation of impurities. Monitoring and understanding the chemical compatibility between components are critical to mitigating stability concerns.[30]

Oxidation and Photodegradation: Certain drugs are prone to oxidation or photodegradation, and the formulation's susceptibility to these processes must be considered. Oxidative reactions can lead to the formation of degradation products, affecting drug stability, while exposure to light may induce photolytic reactions. Protective measures, such as the inclusion of antioxidants or light-blocking materials, may be necessary to address these challenges.

Addressing stability issues is pivotal for the successful development and commercial viability of solid dispersion formulations. Robust stability testing under various conditions, appropriate packaging, and strategic selection of excipients are key strategies to enhance the stability of solid dispersions.[31]

B. Regulatory Considerations

1. Approval Pathways

Regulatory Pathways for Solid Dispersion Formulations: Navigating regulatory approval pathways is crucial for the successful introduction of solid dispersion formulations into the market. Depending on the nature of the drug and the specific formulation, different regulatory routes may be applicable. Understanding and adhering to these pathways are essential for obtaining regulatory approval.

New Drug Application (NDA): For novel drug entities or significant modifications to existing drugs, the submission of an NDA to regulatory authorities is often required. This involves comprehensive documentation of preclinical and clinical data, including safety, efficacy, and quality aspects of the solid dispersion formulation.

Abbreviated New Drug Application (ANDA): If the solid dispersion formulation is intended as a generic version of an already approved drug, an ANDA may be the appropriate regulatory pathway. Demonstrating bioequivalence to the reference product is a key requirement in this context.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

2. Quality Control and Assurance

Establishing Robust Quality Control Measures: Ensuring the quality, safety, and efficacy of solid dispersion formulations requires the implementation of rigorous quality control and assurance measures throughout the manufacturing process. Key considerations include:

Analytical Methods and Specifications: Developing and validating analytical methods to assess the quality of solid dispersions. Specifications should be established for critical quality attributes, ensuring consistency and adherence to predefined standards.

Good Manufacturing Practices (GMP): Adhering to GMP standards to guarantee the quality and safety of the manufacturing process. GMP regulations outline the requirements for the design, monitoring, and control of manufacturing facilities and processes.

Stability Testing: Conducting stability studies under various conditions to assess the long-term stability and shelf-life of the solid dispersion formulation. Stability data are crucial for supporting shelf-life claims and ensuring product quality over time.

Batch-to-Batch Consistency: Implementing strategies to achieve batch-to-batch consistency, minimizing variability in product performance. Process validation and ongoing monitoring contribute to maintaining consistent quality.

Addressing regulatory considerations involves close collaboration with regulatory agencies, adherence to established guidelines, and a commitment to meeting the highest standards of quality control and assurance. Successful regulatory compliance is paramount for market approval and the commercial success of solid dispersion formulations.

VII. FUTURE PERSPECTIVES AND EMERGING TRENDS

A. Advances in Formulation Technologies

1. Nanotechnology Applications

Nanoparticles for Enhanced Drug Delivery: The integration of nanotechnology in solid dispersion formulations holds promise for advancing drug delivery. Nanoparticles, particularly those employing biocompatible materials, enable targeted drug delivery, improved bioavailability, and controlled release. The use of nano-sized carriers, such as liposomes or polymeric nanoparticles, enhances the solubility and stability of BCS Class 2 drugs in solid dispersions. Additionally, surface modification techniques can facilitate targeted delivery to specific tissues or cells.[32]

2. 3D Printing in Solid Dispersion Development

Customized Tablets for Personalized Medicine: 3D printing technology is emerging as a transformative tool in the development of solid dispersion formulations. This approach allows for the fabrication of customized tablets with precise control over drug release profiles. Personalized medicine can be achieved by tailoring formulations to individual patient needs, considering factors such as drug dosage, release kinetics, and therapeutic requirements. 3D printing offers versatility in design, allowing for complex structures and multi-layered tablets to optimize drug delivery.

Advantages of 3D Printing:

Dose Individualization: Tailoring drug doses based on patient-specific requirements.

Complex Formulations: Creating intricate structures and combinations of multiple drugs in a single dosage form.

Rapid Prototyping: Accelerating the development process with rapid prototyping capabilities.

Improved Patient Compliance: Customizing tablets to enhance palatability and ease of administration.

The exploration of nanotechnology applications and the integration of 3D printing technologies represent exciting avenues for the future of solid dispersion formulations. These advancements have the potential to revolutionize drug delivery strategies, providing more effective and personalized therapeutic options for patients.[33]

B. Tailoring Solid Dispersions for Specific Drug Classes

1. Challenges and Opportunities for Diverse BCS Class 2 Drugs

Diversity in Physicochemical Properties: BCS Class 2 drugs encompass a wide range of compounds with varying physicochemical properties, posing both challenges and opportunities in solid dispersion development. The diverse characteristics of these drugs, including different molecular weights, solubilities, and stability profiles, require tailored approaches to achieve optimal formulations.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Challenges:

Variable Solubility: BCS Class 2 drugs exhibit diverse solubility profiles, ranging from poorly soluble to moderately soluble. Formulating solid dispersions that address the specific solubility challenges of each drug is a complex task.

Stability Concerns: Some BCS Class 2 drugs may be susceptible to stability issues, including degradation or polymorphic transformations. Ensuring the stability of solid dispersions for a diverse range of drugs is critical.

Opportunities:

Amorphous State Optimization: Tailoring the solid dispersion formulation to achieve and maintain the amorphous state can enhance solubility for a variety of BCS Class 2 drugs. Innovative approaches, such as the use of stabilizers or novel carriers, offer opportunities to overcome stability challenges.

Combination Approaches: Combining solid dispersions with other delivery technologies, such as lipid-based formulations or nanotechnology, provides opportunities to address the diverse challenges associated with different BCS Class 2 drugs.

2. Personalized Medicine Implications

Tailoring Solid Dispersions for Individual Patients: The concept of personalized medicine involves customizing drug therapies to individual patient needs. Tailoring solid dispersions for specific drug classes aligns with this paradigm, offering the potential for more effective and patient-centric treatments.

Implications:

Dose Individualization: Customizing the dosage of BCS Class 2 drugs in solid dispersions based on patient-specific factors, such as metabolism, age, and disease state, can optimize therapeutic outcomes.

Patient Compliance: Tailored formulations can enhance patient compliance by addressing individual preferences, such as dosage form, taste, and ease of administration.

Therapeutic Precision: Fine-tuning drug release profiles and optimizing formulations for specific patient populations contribute to therapeutic precision, improving overall treatment efficacy.

Tailoring solid dispersions for specific drug classes, considering the challenges and opportunities inherent in BCS Class 2 drugs, opens avenues for advancing drug delivery strategies and aligning with the principles of personalized medicine. This approach holds the potential to revolutionize the treatment landscape for diverse patient populations.[34,35]

VIII. CONCLUSION

A. Summary of Key Findings

In summary, the exploration of controlled release tablets through innovative approaches in modulating gastrointestinal absorption, particularly with the use of solid dispersions, has unveiled several key findings:

Significance of Controlled Release Tablets: The review highlighted the importance of controlled release tablets in achieving sustained and targeted drug delivery, emphasizing their potential for improving therapeutic outcomes and patient compliance.

Challenges in Gastrointestinal Absorption: Physiological considerations, variability in gastric emptying times, and pH-dependent solubility issues were identified as challenges in achieving controlled release through gastrointestinal absorption.

Conventional and Novel Approaches: Conventional methods, such as enteric coatings and modified-release formulations, were discussed alongside their limitations. The review delved into novel strategies, including bioresponsive materials, carrier systems, and prodrug approaches, showcasing their potential in overcoming challenges associated with conventional methods.

Technological Advances:Microfabrication techniques and 3D printing emerged as cutting-edge technologies with the potential to revolutionize controlled release tablet development. The precision offered by these techniques allows for customized tablets, opening new possibilities for tailored drug delivery.

In Vitro and In Vivo Assessment: The importance of robust in vitro models, including simulated gastric and intestinal conditions, and relevant in vivo studies using animal models and clinical trials, was emphasized for evaluating the performance of controlled release tablets.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

Challenges and Future Perspectives: Addressing challenges related to biopharmaceutical variability and regulatory considerations were identified as critical for the successful translation of innovative approaches into practical applications.

B. Implications for Drug Development and Future Research

The implications derived from this review have profound significance for drug development and future research endeavors:

Guidance for Formulation Development: The insights provided into conventional and novel approaches for controlled release tablets serve as a guide for formulators, offering a comprehensive understanding of strategies to enhance drug absorption.

Foundation for Innovation: The exploration of technological advances, such as microfabrication techniques and 3D printing, lays the foundation for innovative avenues in controlled release tablet development. These technologies have the potential to revolutionize drug delivery and pave the way for personalized medicine.

Research Opportunities: The identified challenges, particularly in addressing biopharmaceutical variability and navigating regulatory considerations, present opportunities for further research. Future studies can focus on refining existing approaches, developing new technologies, and advancing our understanding of personalized drug delivery.

In conclusion, the review not only consolidates current knowledge on controlled release tablets but also charts a course for future research and development, pointing towards a more sophisticated and tailored approach to drug delivery. The intersection of conventional wisdom and cutting-edge innovation creates a dynamic landscape with immense potential for improving patient outcomes and advancing the field of pharmaceutical sciences.

REFERENCES

[1]. Asim, M. H., Nazir, I., Jalil, A., Laffleur, F., Matuszczak, B., &Bernkop-Schnürch, A. (2020). Per-6-Thiolated Cyclodextrins: A Novel Type of Permeation Enhancing Excipients for BCS Class IV Drugs. *ACS applied materials & interfaces*, *12*(7), 7942–7950. https://doi.org/10.1021/acsami.9b21335

[2]. Kano, T., Kakinuma, C., Wada, S., Morimoto, K., &Ogihara, T. (2011). Enhancement of drug solubility and absorption by copolymers of 2-methacryloyloxyethyl phosphorylcholine and n-butyl methacrylate. *Drug metabolism and pharmacokinetics*, *26*(1), 79–86. https://doi.org/10.2133/dmpk.dmpk-10-rg-070

[3]. Liu, L., Zou, D., Zhang, Y., Zhang, Q., Feng, Y., Guo, Y., Liu, Y., Zhang, X., Cheng, G., Wang, C., Zhang, Y., Zhang, L., Wu, L., Chang, L., Su, X., Duan, Y., Zhang, Y., & Liu, M. (2020). Pharmaceutical salts/cocrystals of enoxacin with dicarboxylic acids: Enhancing in vitro antibacterial activity of enoxacin by improving the solubility and permeability. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur PharmazeutischeVerfahrenstechnike.V*, *154*, 62–73. https://doi.org/10.1016/j.ejpb.2020.06.018

[4]. Pérez-Carreón, K., Martínez, L. M., Videa, M., Cruz-Angeles, J., Gómez, J., &Ramírez, E. (2023). Effect of Basic Amino Acids on Folic Acid Solubility. *Pharmaceutics*, *15*(11), 2544. https://doi.org/10.3390/pharmaceutics15112544

[5]. Deshmukh, D. D., Nagilla, R., Ravis, W. R., &Betageri, G. V. (2010). Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model. *Drug delivery*, *17*(3), 145–151. https://doi.org/10.3109/10717541003604882

[6]. Dave, V. S., Gupta, D., Yu, M., Nguyen, P., & Varghese Gupta, S. (2017). Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules. *Drug development and industrial pharmacy*, *43*(2), 177–189. https://doi.org/10.1080/03639045.2016.1269122

[7]. Saha, P., & Kou, J. H. (2000). Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur PharmazeutischeVerfahrenstechnike.V*, *50*(3), 403–411. https://doi.org/10.1016/s0939-6411(00)00113-2

[8]. Heinen, C., Reuss, S., Saaler-Reinhardt, S., &Langguth, P. (2013). Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, March 2024

carrageenans. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur PharmazeutischeVerfahrenstechnike.V*, *85*(1), 26–33. https://doi.org/10.1016/j.ejpb.2013.03.010

[9]. Xia, B., Heimbach, T., Lin, T. H., Li, S., Zhang, H., Sheng, J., & He, H. (2013). Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound. *AAPS PharmSciTech*, *14*(3), 1255–1266. https://doi.org/10.1208/s12249-013-0018-2

[10]. Abdelkader, A., Nallbati, L., & Keck, C. M. (2023). Improving the Bioactivity of Norfloxacin with Tablets Made from Paper. *Pharmaceutics*, *15*(2), 375. https://doi.org/10.3390/pharmaceutics15020375

[11]. Kristin, F., René, H., Boontida, M., Buraphacheep, J. V., Maximilian, A., Johanna, M., & Peter, L. (2017). Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, *101*, 211–219. https://doi.org/10.1016/j.ejps.2017.02.003

[12]. Bertoni, S., Albertini, B., &Passerini, N. (2020). Different BCS Class II Drug-Gelucire Solid Dispersions Prepared by Spray Congealing: Evaluation of Solid State Properties and In Vitro Performances. *Pharmaceutics*, *12*(6), 548. https://doi.org/10.3390/pharmaceutics12060548

[13]. Zvonar, A., Berginc, K., Kristl, A., &Gasperlin, M. (2010). Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. *International journal of pharmaceutics*, *388*(1-2), 151–158. https://doi.org/10.1016/j.ijpharm.2009.12.055

[14]. Tong, H. H., Du, Z., Wang, G. N., Chan, H. M., Chang, Q., Lai, L. C., Chow, A. H., &Zheng, Y. (2011). Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound. *International journal of pharmaceutics*, *404*(1-2), 148–158. https://doi.org/10.1016/j.ijpharm.2010.11.027

[15]. Payghan, S., Payghan, V., Nangare, K., Dahiwade, L., Khavane, K., &Phalke, R. (2022). Preparation and Characterization of OrlistatBionanocomposites Using Natural Carriers. *Turkish journal of pharmaceutical sciences*, *19*(2), 168–179. https://doi.org/10.4274/tjps.galenos.2021.71363

[16]. Wahlang, B., Pawar, Y. B., & Bansal, A. K. (2011). Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur PharmazeutischeVerfahrenstechnike.V*, *77*(2), 275–282. https://doi.org/10.1016/j.ejpb.2010.12.006

[17]. Kesisoglou, F., Xie, I. H., Manser, K., Wu, Y., Hardy, I., & Fitzpatrick, S. (2014). Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate. *Journal of pharmaceutical sciences*, *103*(2), 636–642. https://doi.org/10.1002/jps.23837

[18]. Ates, M., Kaynak, M. S., &Sahin, S. (2016). Effect of permeability enhancers on paracellular permeability of acyclovir. *The Journal of pharmacy and pharmacology*, *68*(6), 781–790. https://doi.org/10.1111/jphp.12551

[19]. Prabhu, P., &Patravale, V. (2016). Dissolution enhancement of atorvastatin calcium by co-grinding technique. *Drug delivery and translational research*, *6*(4), 380–391. https://doi.org/10.1007/s13346-015-0271-x

[20]. Prabhu, P., &Patravale, V. (2016). Dissolution enhancement of atorvastatin calcium by co-grinding technique. *Drug delivery and translational research*, *6*(4), 380–391. https://doi.org/10.1007/s13346-015-0271-x

[21]. Pujara, N., Giri, R., Wong, K. Y., Qu, Z., Rewatkar, P., Moniruzzaman, M., Begun, J., Ross, B. P., McGuckin, M., &Popat, A. (2021). pH - Responsive colloidal carriers assembled from β-lactoglobulin and Epsilon poly-L-lysine for oral drug delivery. *Journal of colloid and interface science*, *589*, 45–55. https://doi.org/10.1016/j.jcis.2020.12.054

[22]. Linn, M., Collnot, E. M., Djuric, D., Hempel, K., Fabian, E., Kolter, K., & Lehr, C. M. (2012). Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. *European journal of*

pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, *45*(3), 336–343. https://doi.org/10.1016/j.ejps.2011.11.025

[23]. Nijhawan, M., Santhosh, A., Babu, P. R., &Subrahmanyam, C. V. (2014). Solid state manipulation of lornoxicam for cocrystals--physicochemical characterization. *Drug development and industrial pharmacy*, *40*(9), 1163–1172. https://doi.org/10.3109/03639045.2013.804834

[24]. He, X., Wei, Y., Wang, S., Zhang, J., Gao, Y., Qian, S., Pang, Z., &Heng, W. (2022). Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ΔpK_a Rule. *Pharmaceutical research*, *39*(9), 2263–2276. https://doi.org/10.1007/s11095-022-03335-6

[25]. Beloqui, A., Solinís, M. Á., Gascón, A. R., del Pozo-Rodríguez, A., des Rieux, A., &Préat, V. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. *Journal of controlled release : official journal of the Controlled Release Society*, *166*(2), 115–123. https://doi.org/10.1016/j.jconrel.2012.12.021

[26]. Wu, L., Qiao, Y., Wang, L., Guo, J., Wang, G., He, W., Yin, L., & Zhao, J. (2015). A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats. *AAPS PharmSciTech*, *16*(5), 1051–1058. https://doi.org/10.1208/s12249-014-0280-y

[27]. Patel, K., Doddapaneni, R., Patki, M., Sekar, V., Bagde, A., & Singh, M. (2019). Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. *AAPS PharmSciTech*, *20*(3), 135. https://doi.org/10.1208/s12249-019-1332-0

[28]. Nkansah, P., Antipas, A., Lu, Y., Varma, M., Rotter, C., Rago, B., El-Kattan, A., Taylor, G., Rubio, M., & Litchfield, J. (2013). Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. *Journal of controlled release : official journal of the Controlled Release Society*, *169*(1-2), 150–161. https://doi.org/10.1016/j.jconrel.2013.03.032

[29]. Vadher, A. H., Parikh, J. R., Parikh, R. H., & Solanki, A. B. (2009). Preparation and characterization of co-grinded mixtures of aceclofenac and neusilin US2 for dissolution enhancement of aceclofenac. *AAPS PharmSciTech*, *10*(2), 606–614. https://doi.org/10.1208/s12249-009-9221-6

[30]. Deshmukh, D. D., Ravis, W. R., &Betageri, G. V. (2008). Improved delivery of cromolyn from oral proliposomal beads. *International journal of pharmaceutics*, *358*(1-2), 128–136. https://doi.org/10.1016/j.ijpharm.2008.02.026

[31]. Tian, Y., Booth, J., Meehan, E., Jones, D. S., Li, S., & Andrews, G. P. (2013). Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions. *Molecular pharmaceutics*, *10*(1), 236–248. https://doi.org/10.1021/mp300386v

[32]. Rachmawati, H., Pradana, A. T., Safitri, D., &Adnyana, I. K. (2017). Multiple Functions of D-α-Tocopherol Polyethylene Glycol 1000 Succinate (TPGS) as Curcumin Nanoparticle Stabilizer: In Vivo Kinetic Profile and Anti-Ulcerative Colitis Analysis in Animal Model. *Pharmaceutics*, *9*(3), 24. https://doi.org/10.3390/pharmaceutics9030024

[33]. Lohani, S., Cooper, H., Jin, X., Nissley, B. P., Manser, K., Rakes, L. H., Cummings, J. J., Fauty, S. E., &Bak, A. (2014). Physicochemical properties, form, and formulation selection strategy for a biopharmaceutical classification system class II preclinical drug candidate. *Journal of pharmaceutical sciences*, *103*(10), 3007–3021. https://doi.org/10.1002/jps.24088

[34]. Himawan, A., Djide, N. J. N., Mardikasari, S. A., Utami, R. N., Arjuna, A., Donnelly, R. F., &Permana, A. D. (2022). A novel in vitro approach to investigate the effect of food intake on release profile of valsartan in solid dispersion-floating gel in-situ delivery system. *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, *168*, 106057. https://doi.org/10.1016/j.ejps.2021.106057

[35]. Chen, T., Li, C., Li, Y., Yi, X., Wang, R., Lee, S. M., &Zheng, Y. (2017). Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity. *ACS applied materials & interfaces*, *9*(11), 9516–9527. https://doi.org/10.1021/acsami.7b01171